LUCIUS 卢修斯 劳拉替尼 Lorlatinib ALK阳性肺癌

劳拉替尼

美国FDA批准上市产品,疗效确切
卢修斯制药(老挝)有限公司出品

Lorlatinib

老挝国家食药监局批准上市
老挝国家药检所检测认证

cach film-coated LuciLorla tablet contains:

ALK阳性肺癌

orlatimb 100mg

LUCIUS
PHARMACEUTICALS

Indication:
LuciLorla is for the treatment of adult patient
with metastatic non-small cell lung cancet
(NSCLC)

LuciLorla

Dosage and U
Recommended dosage: 100 mg orally once dail
Severe Renal Impairment: 75 mg orally once

Lorlatinib Tablets

daily.

Rx Only

100mg

FDA批准

Storage: in a dry place and store at 20C 1o25°℃.
Keep medicine out of the reach of Children. Do
not administered LuciLorla in Pregnancy and
Lactation patient treatment.
PLEASE SEE PACKAGE INSERT
Manufactured and Marketed by
LUCIUS

Thongmang village, Xaythany district,

权威认证

Vientiane Capital, Laos
www.lucius.la
Warning and Precaution: lo be soid
by retail on prescription ol a Kegisicicu
oncologist only, and as directed by the

pbvsicin

30 Tablets

口碑质量

适应症:

适用于治疗成年转移性非小细胞肺癌 NSCLC)患者:
其肿瘤经检测呈间变性淋巴瘤激酶(ALK)阳性。
推荐剂量:
1、每日1次:每次口服100mg;
2、严重肾损伤:每日一次,每次口服75mg。